MedTrace Logo

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07336940 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-04-01

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms.

The main questions it will answer are:

* Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis?
* Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study.

Participants will:

* Take drug ENV-294 once every day for 28 days
* Visit the clinic weekly for 4 weeks for checkups and tests
* Keep a diary of their symptoms and when they took their study drug ENV-294

Conditions

  • Atopic Dermatitis (AD)

Interventions

DRUG

ENV-294 Capsule

ENV-294 formulated as 200mg capsules for oral administration will be used for this study.

Sponsors & Collaborators

  • Enveda Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-10
Primary Completion
2026-01-13
Completion
2026-01-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07336940 on ClinicalTrials.gov